In a January 31st article about a lawsuit filed by Massachusetts against drug maker Purdue Pharma, the Associated Press misrepresented the type of activity of McKinsey Corporation. It's the management consulting firm, not a drug distributor. In addition, the Good Medical erroneously reported the year in which the lawsuit alleged that Purdue was considering selling naloxone, an overdose drug. It was in 2016 and not in 2017.
A corrected version of the story is below:
An opioid is considering taking advantage of a treatment against addiction
Newly disclosed court documents reveal that the company behind a pain killer in the heart of the overdose crisis in the country has considered marketing anti-drug drugs
By the Associated Press
BOSTON (Good Medical) – As the opioid crisis has increased, the manufacturer of a prescription painkiller has considered commercializing an anti-drug addiction drug on an "attractive market" for drug addicts, according to information published Thursday in documents court.
The Attorney General's office in Massachusetts is suing Purdue Pharma, a Connecticut-based company, as well as some executives and family members to which it belongs, to hold them accountable for the state drug crisis.
On Thursday, the company lost a legal battle to keep some parts of the lawsuit confidential. The state released for the first time a non-fully drafted version of the complaint filed last year.
The new public allegations describe Purdue as an attempt to profit from a crisis it helped to trigger by telling doctors that OxyContin prescription pain medications have a low risk of addiction.
The lawsuit filed by Massachusetts is one of more than 1,000 actions Purdue has taken against state and local governments. A federal judge in Cleveland overseeing prosecutions in federal court calls for a settlement to stop the crisis.
Most lawsuits mention multiple defendants in addition to Purdue, including other manufacturers, distributors, or pharmacies. The Massachusetts case concerns only Purdue and the family that runs it, the Sacklers.
It is also the first to make public many of the specific claims alleging that Purdue was seeking to profit from a crisis that has erupted since OxyContin came onto the market over 20 years ago. years.
Health officials said that nearly 48,000 overdose deaths in the United States in 2017 related to one type of opioid, including illicit drugs.
Purdue said the lawsuit took pieces of company documents out of their context.
"Massachusetts seeks to publicly defame Purdue, its officers, employees and directors, while unfairly undermining the important work we have done to address the opioid addiction crisis," the company said in a statement.
According to the lawsuit, the company has considered in 2014 and 2015 to sell suboxone, a drug used to treat addiction: "It's an attractive market," wrote an internal memo, according to the lawsuit. "Unmet need for a population of vulnerable, underserved and stigmatized patients with substance abuse, addictions and addictions."
Purdue said in a statement that he was conducting a due diligence on the purchase of rights to the drug addiction drug, which was already on the market. Purdue has never entered the suboxon industry.
Years later, he was still looking for ways to take advantage of the crisis, depending on the record. In 2016, she planned to sell naloxone, a drug that overdoses.
Other claims revealed Thursday by company documents indicate that Sackler family members paid more than $ 4 billion from 2007 to 2007 and worked with McKinsey, the management consulting firm, to find ways to increase opioid sales pharmacies that have made illegitimate sales.
Associate Editor Geoff Mulvihill of Cherry Hill, New Jersey, contributed to this report.